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Abstract
 
To study the role of Fas–Fas ligand (FasL) interaction-mediated apoptosis in lymphocyte ho-
meostasis, we generated a mutant fas allele allowing conditional inactivation of the fas gene
through Cre-mediated recombination. Experiments in which Fas was ablated in T cells, B
cells, T and B cells, or in a more generalized manner demonstrated that the development of
lymphoproliferative disease as seen in Fas-deficient mice requires Fas ablation in lymphoid and
nonlymphoid tissues. Selective inactivation of Fas in T cells led to a severe lymphopenia over
time, accompanied by up-regulation of FasL on activated T cells and apoptosis of peripheral
lymphocytes. In addition, the mutant animals developed a fatal wasting syndrome caused by
massive leukocyte infiltration in the lungs together with increased inflammatory cytokine pro-
duction and pulmonary fibrosis. Inhibition of Fas–FasL interaction in vivo completely pre-
vented the loss of lymphocytes and initial lymphocyte infiltration in the lungs. Thus, FasL-me-
diated interaction of activated, Fas-deficient T cells with Fas-expressing cells in their
environment leads to break down of lymphocyte homeostasis and development of a lung dis-
ease strikingly resembling idiopathic pulmonary fibrosis in humans, a common and severe dis-
ease for which the mutant mice may serve as a first animal model.
Key words: lymphocyte homeostasis • lymphopenia • apoptosis • lungs • 
conditional gene targeting
 
Introduction
 
Fas (CD95/Apo-1) is a member of the TNF-R family ex-
pressed on a variety of cells, including thymocytes, T cells,
activated B cells, macrophages, and neutrophils, as well as or-
gans such as liver, lung, and heart (1). Engagement of Fas by
Fas ligand (FasL) or agonist anti-Fas antibody induces Fas-
positive cells to undergo apoptosis (2). FasL is a TNF-related
type II transmembrane molecule predominantly expressed
on activated T and natural killer cells, as well as in immune
privilege sites such as testis, eye, and brain (1). Fas–FasL in-
teractions down-regulate immune responses through the in-
duction of apoptosis of activated Fas-positive cells during im-
mune response (2). The mutation of Fas in 
 
lpr
 
 or FasL in 
 
gld
 
mice leads to autoantibody production and lymphoprolifera-
tive disease (3, 4) and, in humans, to a severe autoimmune
lymphoproliferative syndrome (ALPS; references 5, 6). The
cellular basis of ALPS is not well understood, although T
cells clearly play a critical role, given that lymphprolifera-
tion involves a peculiar type of T cell (so-called “double
negative” [DN] cells, whose immunophenotype is Thy1
 
 
 
B220
 
 
 
CD4
 
 
 
CD8
 
 
 
) and is prevented by thymectomy (7, 8).
Furthermore, transgenic restoration of Fas expression in T
cells of 
 
lpr
 
 mice rescues the mice from lymphoproliferative
disease (9, 10). B cells also seem to be involved in the lpr
syndrome because, in B cell–deficient lpr mice, lymphopro-
liferation is largely inhibited (11). However, Fas deletion in
lymphocytes per se does not seem to be sufficient to cause
ALPS because the transfer of BM cells from MRL
 
lpr
 
/
 
lpr
 
 mice
to lethally irradiated congenic wild-type recipients results in
a severe wasting syndrome instead, resembling GVHD (12,
13). However, GVHD did not develop when BM from
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MRL mice lacking both Fas and FasL was transferred (14).
This suggests that the development of GVHD in this transfer
system may be based on the interaction of Fas-deficient T
cells with Fas-expressing cells in the environment through
Fas–FasL interaction, and that the development of ALPS re-
quires the absence of Fas on lymphocytes and nonlymphoid
cells. Paradoxically, tetraparental mice derived from the fu-
sion of 
 
lpr
 
 and wild-type blastocysts were found not to de-
velop a GVHD-like wasting syndrome, but rather the typical
 
lpr
 
 phenotype characterized by lymphoproliferation and au-
toantibody production, respectively (15, 16).
To clarify these matters, it seemed desirable to establish a
system in which Fas is selectively inactivated in a tissue-spe-
cific or inducible manner in the intact mouse, thus avoiding
complications from cell transfers and whole-body X-irradia-
tion, which by itself causes cellular damage and makes the
animal prone to disease. Therefore, we have generated a
mouse strain allowing conditional Fas inactivation upon Cre
recombination. We find that, on the C57BL/6 genetic back-
ground, mutant animals with Fas inactivation in T cells, B
cells, or both types of cells do not develop ALPS, and an
attenuated form of the disease develops under these condi-
tions on the autoimmune-prone (C57BL/6
 
 
 
MRL)F1 back-
ground, compared with the disease resulting from fas gene
inactivation in the germ line. However, T cell–specific Fas
inactivation in C57BL/6 mice leads to a FasL-dependent
profound T and B cell deficiency over time, together with a
chronic inflammatory and fatal lung disease strikingly resem-
bling idiopathic pulmonary fibrosis (IPF) in humans (17).
 
Materials and Methods
 
Generation of Conditional fas KO Mice. 
 
A clone containing
the 
 
fas
 
 genomic locus was provided by S. Nagata (Osaka Univer-
sity Medical School, Osaka, Japan). A gene-targeting construct
was generated to flank exon IX coding for the death domain by
two 
 
loxP
 
 sites. Through standard cloning, a 
 
loxP
 
 site and a 
 
loxP
 
-
flanked neomycin-resistant cassette were cloned into the upstream
and downstream of exon IX, respectively. The thymidine kinase
(
 
tk
 
) gene was added to the 5
 
 
 
 ends of the targeting vector. Bruce-4
embryonic stem cells derived from C57BL/6 mice were cul-
tured, transfected, and selected as described previously (18). The
homologous recombinant clones were transiently transfected with
a Cre-encoding plasmid to remove the 
 
loxP
 
-flanked neomycin
cassette. Male chimeras were mated with C57BL/6 females to ob-
tain germline transmission of the 
 
fas
 
-floxed allele (
 
fas
 
fl
 
). Deletion
of exon IX encoding the death domain would completely abolish
the apoptotic function of Fas. 
 
Fas
 
fl/fl
 
 mice were crossed to 
 
CD4-cre
 
mice provided by C. Wilson (University of Washington, Seattle,
WA; reference 19) or 
 
lck-cre
 
 (20) and 
 
CD19-cre
 
 transgenic mice
(21) to achieve T and B cell–specific Fas ablation. Mice with Fas
inactivation in both T and B cells were obtained by combining
the two 
 
cre
 
 alleles with the 
 
fas
 
fl
 
 allele. To establish a system of in-
ducible 
 
fas
 
 inactivation, 
 
fas
 
fl/fl
 
 mice were bred with 
 
Mx-cre
 
 trans-
genic mice in which the cre transgene is under the control of the
type I IFN-inducible 
 
Mx
 
 promoter (22). All mice used had been
backcrossed to C57BL/6 for 5–10 generations unless otherwise
stated. For the study of lymphoproliferation on the (C57BL/
6
 
 
 
MRL)F1 background, we crossed tissue-specific Fas KO mice
on the C57BL/6 background with MRL
 
lpr/lpr
 
 mice. All mice used
in this work were housed in a conventional animal facility in the
Institute for Genetics, Cologne, Germany. All animal studies were
approved by the institutional review board.
 
Induced Generalized Inactivation of fas. 
 
To induce generalized
Cre expression and subsequent inactivation of 
 
fas
 
, 8–10-wk-old mice
of the genotype 
 
fas
 
fl/fl
 
 and 
 
fas
 
fl/fl
 
, Mx-cre were given 3 
 
 
 
 400 
 
 
 
g
Poly(I) 
 
  
 
Poly(C) (Amersham Biosciences) i.p. on days 0, 3, and 6.
 
Assessment of Lymphoproliferation. 
 
To evaluate the severity of
lymphoproliferative disease, spleens were weighed and analyzed
for DN (i.e., Thy1
 
 
 
B220
 
 
 
CD4
 
 
 
CD8
 
 
 
) cells by FACS
 
®
 
. All en-
larged LNs were weighed, and only the biggest LN was analyzed
by FACS
 
®
 
 in mice displaying lymphadenopathy; inguinal and
cervical LNs were collected for weight and FACS
 
®
 
 analysis in an-
imals that did not display unusually big LNs.
 
Flow Cytometry. 
 
10
 
6
 
 lymphoid cells were stained with fluo-
rochrome- (FITC, PE, or Cychrome) or biotin-conjugated
monoclonal antibodies for flow cytometric analysis. Streptavidin-
Cychrome was used to reveal biotinylated antibodies. The fol-
lowing homemade mAbs were used: R33-24-12 (anti-IgM), 1.3-
5 (anti-IgD), RA3-6B2 (anti-B220), and Thy1.2 (Cfo 1). mAbs
against active caspase-3, CD3, CD4, CD8, CD19, CD25, CD44,
CD69, CD62L, annexin V, Fas (Jo2), and FasL (MFL3) were
purchased from BD Biosciences. Staining of LN cells with anti-
FasL antibody (MFL3) was performed in the presence of a matrix
metalloproteinase inhibitor from BD Biosciences. Staining of LN
cells for active (cleaved) caspase-3 was performed according to
the manufacturer’s instruction (BD Biosciences).
 
Immunohistology. 
 
Lungs inflated with 50% OCT in PBS and
spleens were embedded in OCT and frozen on dry ice. Frozen
sections were cut, air-dried, and fixed with cold (
 
 
 
20
 
 
 
C) ace-
tone. For immunostaining, sections were rehydrated in PBS and
stained with monoclonal antibodies against mouse CD3, CD19,
Gr1 (BD Biosciences), and F4/80 (Serotec) followed by alkaline
phosphatase–conjugated goat anti–rat IgG (Jackson ImmunoRe-
search Laboratories) or streptavidin-peroxidase/streptavidin-alka-
line phosphatase (Boehringer) for biotinylated antibody. After
washing, bound peroxidase was revealed by 3-amino-9-ethyl car-
bazole (Sigma-Aldrich), and biotin by alkaline phosphatase sub-
strate kit III/blue (Vector Laboratories). The TUNEL assay was
done using the DeadEnd™ Fluorometric TUNEL System or
DeadEnd™ Colorimetric TUNEL System (Promega). Hematox-
ylin and eosin staining and elastic fiber staining were performed
according to the manufacturer’s protocol (Sigma-Aldrich).
 
Measurement of Cytokines. 
 
Serum cytokine levels were mea-
sured by ELISA according to the manufacturer’s instructions
(R&D Systems). In addition, lungs were subjected to intrabron-
chial lavage (three washes of 500 
 
 
 
l PBS). Cytokine levels in the
bronchoalveolar lavage fluid (BALF) were measured in the same
way as for the serum.
 
Application of Anti-FasL Antibody In Vivo. 
 
Anti–mouse FasL
mAb MFL1 or MFL3 (23), or isotype-matched hamster IgG1
(BD Biosciences) were injected intravenously (0.3 mg/mouse,
twice a week) or intraperitoneally (0.5 mg/mouse, twice a week)
into 14-wk-old 
 
fas
 
fl/fl
 
 and 
 
fas
 
fl/fl
 
, 
 
CD4-cre
 
 mice. 8 or 12 wk after
administration, animals were killed and analyzed for cellularity in
the lymphoid organs and immunohistology of spleens and lungs.
 
Results
 
Generation of a Mouse Strain Allowing Tissue-specific Inacti-
vation of Fas. 
 
A conditional 
 
fas
 
 allele (
 
fas
 
fl
 
) in which the
death domain–encoding exon IX flanked by 
 
lox/P
 
-sites
(Fig. 1, a and b) was generated to allow conditional inacti- 
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vation of Fas through cell type–specific expression of Cre
recombinase. Fas
 
fl/fl
 
 mice showed normal lymphocyte de-
velopment and subset distribution as determined by FACS
 
®
 
analysis (unpublished data). Deletion of the 
 
loxP
 
-flanked
(floxed) fas sequence through crossing to the 
 
deleter
 
 strain
(24) produced mice carrying an inactive 
 
fas
 
 allele (
 
fas
 
del
 
) in
all cells of the body. As expected, 
 
fas
 
del/del
 
 mice developed
the typical 
 
lpr
 
 phenotype (unpublished data). To delete Fas
selectively in T cells, 
 
fas
 
fl/fl
 
 mice were crossed to 
 
CD4
 
-
 
cre
 
transgenic mice in which the cre coding sequence is under
the control of a CD4 minigene (19). Southern blot analysis
of DNA isolated from thymus and various cell populations
in the spleen of 
 
fas
 
fl/fl
 
, 
 
CD4-cre
 
 mice demonstrated efficient
Cre-mediated recombination in T cells (Fig. 1 c). In the
nonlymphocyte population of the spleen, a band character-
istic for the 
 
fas
 
del
 
 allele was also detectable, but its intensity
(16% of that representing the 
 
fas
 
fl
 
 allele) corresponded to
the fraction of contaminating T cells (17%). The absence of
Fas expression in thymocytes of the compound mutants
was also confirmed by FACS
 
®
 
 analysis at the protein level
(Fig. 1 d). Similarly, efficient Cre-mediated recombination
in B cells, and both T and B cells was observed in 
 
fas
 
fl/fl
 
,
 
CD19-cre
 
 and 
 
fas
 
fl/fl
 
, 
 
CD4-cre/CD19-cre
 
 mice, respectively
(unpublished data).
 
Absence of lpr Disease in C57BL/6 Mice Lacking Fas Selec-
tively on Lymphocytes. 
 
Splenomegaly and lymphadenopa-
thy were evident in 
 
fas
 
del/del
 
 C57BL/6 mice when they be-
came older than 5 mo. In contrast, there was no evidence
for lymphoproliferative disease in 7–9-mo-old mice lacking
Fas on T, B, or both T and B lymphocytes (Fig. 2 a). In the
LNs of these animals, there were almost no DN (i.e.,
Thy1
 
 
 
B220
 
 
 
CD4
 
 
 
CD8
 
 
 
) T cells, they are typically seen
in mice homozygous for the 
 
lpr
 
 mutation. With respect to
autoantibody formation, T or B cell–specific deletion of
Fas led to a three- to eightfold increase of IgM and IgG an-
tibodies specific for single-stranded DNA, but this was still
two- to threefold below the titers seen in 
 
fas
 
del/del
 
 mice (un-
published data). Thus, Fas inactivation in lymphocytes only
is insufficient for the 
 
lpr
 
 disease to occur, indicating that
Fas-defective nonlymphoid cell types are also critically in-
volved in disease development. To prove this point, inacti-
vation of Fas in multiple cell types, including lymphocytes
and nonhematopoietic cells such as liver cells, was induced
in 
 
fas
 
fl/fl
 
, 
 
Mx-cre
 
 mice by injection of Poly(I) 
 
  
 
Poly(C) (22).
As expected, mice with Fas inactivation in both lymphoid
and nonlymphoid cells reconstituted the lymphoprolifera-
tive disease seen in 
 
fas
 
del/del
 
 mice (Fig. 2 a).
Attenuated Lymphoproliferatie Disease in (C57BL/6 
MRL)F1 Mice Lacking Fas Selectively on Lymphocytes.
The lymphoproliferative disease in lpr mice is strongly de-
pendent on the genetic background of the animals (25). To
study the effects of cell type–specific Fas inactivation in
the context of an autoimmune-prone genetic background,
we conditionally inactivated the fas gene in (C57BL/
6 MRL)F1 mice, which are as autoimmune-prone as the
MRL strain itself (26). In contrast with what we had ob-
served in C57BL/6 mice, Fas inactivation in T cells of the
F1 animals led to a 12-fold enlargement of LNs due to the
expansion of the DN T cells typical for the lpr syndrome
(Fig. 2 b). Among five mice analyzed, four had a twofold
enlarged spleen and one had a spleen of normal size. A sim-
ilar enlargement of LNs and spleen (17- and 5-fold, respec-
tively), but no expansion of DN cells was found upon B
cell–specific Fas inactivation. However, in both cases, the
weight of the enlarged LNs was still two to three hundred-
fold below that in faslpr/del mice. The lymphoproliferative
disease in (C57BL/6 MRL)F1 mice with Fas inactivation
in both T and B cells was not more severe than that seen
upon T cell–specific Fas inactivation; among three mice
analyzed, only one mouse had mildly enlarged LNs (un-
published data). Thus, in contrast with C57BL/6 mice, the
autoimmune-prone animals develop an attenuated lym-
phoproliferative disease upon lymphocyte-specific Fas inac-
tivation, but in both strains, Fas-defective nonlymphoid
cells are critically involved in the full development of
ALPS.
Loss of T and B Cells upon T Cell–specific Fas Inactivation.
Rather than leading to lymphoproliferation, T cell–specific
Fas inactivation resulted in a decline of both T and B cell
numbers in the secondary lymphoid organs over time, and
finally led to an almost complete lymphopenia in the LNs
of the animals (Fig. 3, a and b). The numbers of total cells,
Figure 1. T cell–specific KO of Fas. (a) Targeting scheme. (1) Genomic
structure of the fas locus surrounding exon IX. (2) Targeting vector con-
struction. The chromosomal locus after homologous recombination is
shown in 3. Cre-mediated deletion produces the fas floxed (4, fasfl) and
deleted alleles (5, fasdel). (triangles) loxP sites. Ev, EcoRV; S, SphI; C, ClaI
restriction site. (b) Southern blot analysis on DNA from wild-type em-
bryonic stem cells (Bruce-4) and homologous recombinants (clones 117
and 173 and neor deleted clones 117#5 and 173#5). (c) T cell–specific de-
letion of Fas. T, thymocytes; B, purified splenic B cells (CD19 ); XTB,
purified nonlymphocyte population. Deletion efficiencies are indicated.
(d) FACS® analysis showing loss of Fas expression in thymocytes of fasfl/fl,
CD4-cre mice.Fas–Fas Ligand Interaction-mediated Lymphocyte Homeostasis and Pulmonary Fibrosis 1358
T cells, and B cells in the spleens of T cell–specific Fas KO
mice were  160% of the controls at the age of 2 mo.
However, T cell and B cell counts in the mutants declined
to  60% of the controls at the age of 5 mo, and further to
23% for T cells and 44% for B cells at the age of 7 mo (Fig.
3 a). As with the spleen, cell numbers in the inguinal LNs
of the mutants were comparable to control values at the age
of 2 mo (Fig. 3 a). However, at 5 mo of age, the inguinal
LNs in 6 out of 8 mutant animals analyzed were atrophic
and contained  0.1 million cells. At 7 mo, the inguinal
LNs in all of four mutants analyzed were almost empty.
Similar to the inguinal LNs, age-dependent cell loss was
also observed in other LNs, including mesenteric, axillary,
and cervical LNs (unpublished data). Enlargement of the
spleen (157   27 mg against 85   25 mg in the controls;
n   4) and disruption of splenic architecture characterized
by loss of white pulp, sclerosis, and hyalinization became
evident in the mutants at the age of 5 mo (Fig. 3 b and not
depicted). Flow cytometric analysis showed that 65% of T
cells and 64% of B cells in the LNs of 16-wk-old mutants
were positive for annexin V, a marker for cells undergoing
apoptosis (Fig. 3 c). Similarly, widespread cellular apoptosis
was observed in histological sections of the spleens of the
mutants, whereas, in the controls, apoptotic (TUNEL pos-
itive) cells were rare and exclusively located in the splenic
red pulp (Fig. 3 d). These results indicate that cellular apop-
tosis is the main cause for lymphocyte depletion upon T
cell–specific Fas inactivation. A subset of DCs called “my-
eloid” DCs in mouse spleen is CD4 positive (27) and, thus,
it is possible that the fas gene was also deleted in these cells.
To clarify this point, we bred the fasfl/fl mice to lck-cre trans-
genic mice in which Cre recombinase is only expressed in
T cells but not DCs (20). Similar to fasfl/fl, CD4-cre mice,
the LNs of fasfl/fl, lck-cre mice at the age of 7 mo contained
 0.1 million cells, confirming that loss of T and B cells is
indeed due to Fas deletion in T cells (unpublished data).
The possibility that Cre expression as such is toxic for T
cells was excluded by two pieces of evidence as follows: T
cell numbers in aged fasfl/ , CD4-cre mice were comparable
to those in fasfl/fl controls; and aged fasdel/del; CD4-cre mice
had the expected splenomegaly and lymphadenopathy (un-
published data).
The loss of lymphocytes in the peripheral lymphoid or-
gans of the conditional mutants prompted us to analyze
lymphocyte development in primary lymphoid organs. The
cellularity of the thymus was comparable to that of litter-
mate controls at the age of 2 mo, and declined to  50 and
10% of the controls at the age of 5 and 7 mo, respectively
(unpublished data). Occasionally, the thymi of 7-mo-old
mice were completely involuted as judged by cellular com-
position, and only thymic LNs were detectable in the area
where the thymus is normally localized (unpublished data).
However, thymic atrophy can only partly account for the
severe loss of peripheral T cells, as we have directly dem-
onstrated that in the mutant animals peripheral T and B
cells die by apoptosis (Fig. 3, C and D). We also note
that  conditional recombination-activating gene (RAG)-2
knockout mice (18) still have substantial numbers of pe-
ripheral T cells in the lymphoid organs 7 mo after induc-
tion of RAG-2 deletion ( 25 and 50% of the controls in
LN and spleen, respectively; unpublished data). B cell de-
velopment in the bone marrow of the mutants was undis-
turbed, and peripheral B cells were not activated even in
old animals (not depicted), indicating that, similar to T
cells, the loss of B cells in the secondary lymphoid organs is
due to massive apoptosis (Fig. 3, c and d) rather than a B
cell developmental defect.
Up-Regulation of Activation Markers and FasL on Fas-defi-
cient T Cells.  Approximately 50% of the peripheral T
cells in the T cell–specific Fas KO mice developed an acti-
Figure 2. Defective Fas ex-
pression in nonlymphoid cells is
required for the development
of lymphoproliferative disease.
FACS® analysis of DN T cells in
LNs is shown. (a) 7–9-mo-old
C57BL/6 mice with Fas deletion
in tissue-specific or inducible
manner. Mx–cre-mediated dele-
tion was induced 8 mo before
analysis. (b) Mild lymphadenop-
athy and splenomegaly upon T,
B, and T plus B cell–specific
Fas inactivation in (C57BL/
6 MRL) F1 mice at the age of
5–6 mo. Pictures of spleen and
LNs are shown. Weights are
shown as means   SD (n   
2 6). Cell numbers shown on
top of FACS® plots indicate total
cellularity from the largest LNs
of mice suffering from lymphad-
enopathy or of inguinal or cervi-
cal LNs of mice without appar-
ent lymphadenopathy.Hao et al. 1359
vated phenotype as was evident from the up-regulation of
CD69 at the age of 5 mo, but not 2 mo (Fig. 4 a). Like-
wise, the proportions of CD62Lhigh/CD44low naive and
CD62Llow/CD44high activated/memory T cells among the
CD4 population in the mutants were comparable to those
in the controls at the age of 2 mo, but an increase of the
fraction of activated/memory T cells became evident at the
age of 5 mo. At 7 mo, there were almost no naive T cells in
the spleens of the mutant mice, and 91% of the T cells
were activated/memory cells (Fig. 4 b). A similar trend was
also seen in the case of CD8 T cells, but it was less dramatic
(unpublished data). In parallel, activated T cells from T
cell–specific Fas KO mice expressed very high levels of
FasL that were far beyond those on T cells from fasdel/del
mice at the age of 5 mo, but not 2 mo (Fig. 4 c and not de-
picted). Notably, the loss of lymphocytes in the secondary
lymphoid organs correlated with increasing T cell activa-
tion. Although not explaining the loss of naive T cells, it
appeared possible that the activated T cells appearing in the
animals were directly causing the loss of B cells through
Fas–FasL interaction. To obtain evidence in this direction,
we analyzed the lymphocytes in the mutant animals for the
Figure 3. Loss of peripheral lymphocytes upon T cell–specific Fas inac-
tivation. (a) Cellularity in the spleen and inguinal LNs. Each circle repre-
sents an individual mouse. Lines connect mean values of each group. (b)
Immunohistochemical staining of spleens of 5–6-mo-old mice (four mice
per group analyzed) with anti-CD3 (red) and anti-CD19 (blue) antibody.
(c) Annexin V staining of T and B cells in LNs (four mice per group ana-
lyzed) at the age of 16 wk. (d) TUNEL staining of the splenic sections
from animals (four mice per group analyzed) at the age of 16 wk. Green
and red staining shows apoptotic cells and nuclei, respectively. (b and d)
Bars, 200  m.
Figure 4. Activation and high levels of FasL expression in Fas-deficient
T cells. (a) Expression of the activation marker CD69 on splenic CD3  T
cells. (b) Analysis of CD62L versus CD44 on gated CD4  splenic cells to
determine the proportion of naive (CD62Lhigh/CD44low) and activated/
memory (CD62Llow/CD44high) T cells. (c) FasL expression on gated
CD3  or CD3 CD69  LN cells from 5-mo-old animals. (d) Active cas-
pase-3 activity in T and B cells of LN cells from 18-wk-old mice. Three
to five mice per group were analyzed, and a representative analysis is
shown for each group.Fas–Fas Ligand Interaction-mediated Lymphocyte Homeostasis and Pulmonary Fibrosis 1360
presence of active (cleaved) caspase-3, a marker for cells
undergoing apoptosis upon death receptor engagement or
stress-induced cytochrome c release (2). As shown in Fig. 4
d,  40% of B cells, but no T cells, from the LNs of the
mutants indeed displayed caspase-3 activity.
Development of Inflammatory Pulmonary Fibrosis in Aged fasfl/fl,
CD4-cre Mice.  Accompanying T cell activation and the
loss of lymphocytes, T cell–specific Fas KO mice devel-
oped a severe wasting syndrome after 10 mo (Fig. 5 a,
mouse aged 15 mo). Compared with the controls, the mu-
tant animals lost an average of  30% body weight, and
75% of the mutant animals died within 10–18 mo (Fig. 5 b
and not depicted). Histological analysis of the lungs of 10-
mo-old diseased mutants revealed severe pulmonary fibro-
sis as shown by massive accumulation of elastic fibers, and
intense alveolitis with accumulation of inflammatory cells
including lymphocytes, neutrophils, and activated macro-
phages in the lung parenchyma (Fig. 6 a). Mild to moderate
cellular infiltrations were also seen in the liver and kidney,
and occasionally in the pancreas and colon, but not in the
heart and stomach of the animals (unpublished data). How-
ever, the lung disease was likely the main reason for the ul-
timate death of the animals.
The lung disease in the mutant animals started with in-
terstitial infiltrates of T and B cells predominantly around
arteries and bronchi when the animals reached the age of 5
mo (Fig. 6 b), indicating that lymphocyte infiltration ini-
tiates pulmonary inflammation. This was accompanied by
massive apoptotic cell death, as indicated by the presence of
large numbers of TUNEL-positive cells around the arteries
and bronchi, with a distribution fitting that of the infiltrat-
ing T cells (Fig. 6 b). This suggests a critical role of the lat-
ter cells in the initial lung injury. At later stages of the dis-
ease, TUNEL-positive cells were found scattered in the
lung parenchyma, and there was no longer an apparent
colocalization with T cell infiltrates (Fig. 6 c).
What causes the severe pulmonary disease developing
upon T cell–specific inactivation of Fas? Despite extensive
efforts, we were unable to obtain any evidence for an in-
fectious process involving bacteria, viruses, or intracellular
parasites such as pneumocystis carinii (unpublished data).
This suggests that, rather than being due to immunodefi-
ciency, the disease is likely caused by inflammation initiated
by the interaction of the Fas-deficient T cells with their
Fas-proficient environment. To better understand this in-
teraction and the ensuing inflammatory response, we deter-
mined the levels of various cytokines in the blood and the
BALF in the mutants at the ages of 5 mo and 14–18 mo.
The levels of TGF- 1, TGF- 2, macrophage inflamma-
tory protein 2 (MIP-2), TNF- , IFN- , IL-1 , IL-1 , IL-6,
KC, and soluble FasL in the sera were not significantly
different between mutants and controls at all time points,
Figure 5. Wasting syndrome and increased inflammatory cytokine pro-
duction in aged T cell–specific Fas-deficient mice. (a) A mutant and a
control mouse at the age of 15 mo. (b) Survival of mutant and control an-
imals. (c) MIP-2 and TGF- 1 levels in the BALF at the age of 14 18
mo. Results shown are means   SD (n   3 5).
Figure 6. Leukocyte infiltration in the lungs and development of pul-
monary fibrosis upon T cell–specific Fas inactivation. (a) Histological
analysis of the lungs of mice at the age of 10 mo. H & E, hematoxylin and
eosin staining; Ly-6G, staining for neutrophils (red); F4/80, staining for
macrophages (blue); Elastic Stain, staining of elastic fibers (black blue) and
cell nuclei (black). (b) Immunohistochemical staining of the lungs of 5–6-
mo-old mice with anti-CD3 (red) and anti-CD19 (blue) antibody, and
TUNEL (brown) on serial lung sections. (c) The staining was the same as
in b, except the sections were from mice at the age of 15 mo. Three mice
per group were analyzed, and representative results are shown. Bar,
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and this was also the case for TGF- 2, KC, IL-4, IL-13,
and soluble FasL levels in the BALF of the lungs. However,
the level of the chemokine MIP-2, a functional homologue
of human IL-8 in the mouse (28), was significantly elevated
in the BALF of the mutants at the ages of 14–18 mo, but
not 5 mo (Fig. 5 c). Thus, the neutrophil infiltration in the
lungs of the diseased animals could be caused by the che-
mokine activity of MIP-2 (28). Similarly, the level of the
active form of TGF- 1 in the BALF of the mutants was
drastically increased (Fig. 5 c). Because TGF- 1 has been
shown to play a central role in the development of pulmo-
nary fibrosis in other contexts (29–31), this result suggests
that TGF- 1 is critically involved in the development of
lung fibrosis in the animals selectively lacking Fas in T cells.
Prevention of Loss of Lymphocytes and Initial Lymphocyte In-
filtration in the Lungs upon Blockade of Fas–FasL Interaction.
Together, our results reveal two major consequences of Fas
inactivation selectively in T cells as follows: the loss of pe-
ripheral lymphocytes and the development of a fatal in-
flammatory pulmonary fibrosis. Because it has been re-
ported that the DN (Thy1 B220 CD4 CD8 ) T cells
from lpr mice are cytotoxic against Fas-expressing cells on
the basis of up-regulated FasL expression (32, 33), and the
activated T cells from T cell–specific Fas KO mice abun-
dantly expressed FasL on their surface (Fig. 4 c), we rea-
soned that both the loss of lymphocytes and the pulmonary
disease might be due to FasL-mediated interactions of the
mutant T cells with Fas-expressing cells in their environ-
ment. With respect to lymphocyte loss, the abundant ex-
pression of FasL on T cells could lead to the direct killing
of the (Fas proficient) B cells, and Fas–FasL interactions
could also directly or indirectly be involved in the eventual
depletion of T cells in the mutant animals. If this general
notion were correct, application of a neutralizing anti-FasL
antibody and, hence, inhibition of Fas–FasL interaction
should prevent both lymphopenia and pulmonary disease
in these mice. Based on the fact that T and B cells were lost
rapidly between 2 and 5 mo of age (Fig. 4 a), 14-wk-old
fasfl/fl, CD4-cre mice were chosen for treatment with the
neutralizing anti-FasL antibody MFL-1/3 (23). LN T cells
from the mutant animals expressed high levels of FasL at
this age (unpublished data). Fasfl/fl mice either unmanipu-
lated or treated with anti-FasL antibody or fasfl/fl, CD4-cre
mice treated with isotype-matched hamster IgG1 served as
controls. As shown in Fig. 7 a, loss of T and B cells in the
inguinal LNs from two fasfl/fl, CD4-cre mice 8 wk after the
initiation of anti-FasL treatment was completely prevented.
In a single animal analyzed 12 wk after treatment, the cell
number in the inguinal LNs was reduced to half a million,
but was increased threefold in the spleen as compared with
controls (unpublished data). Substantial numbers of cells re-
sembling those undergoing lymphoproliferation in lpr mice
(Thy1 B220 CD4 CD8 ) were generated in the anti-
FasL antibody-treated mutants (Fig. 7 a). As expected, fasfl/fl,
CD4-cre mice treated with isotype-matched IgG1 lost
their lymph node cells over the time of treatment. In
agreement with these data, immunohistological analysis on
the same set of animals showed that the blockade of Fas–
FasL interaction in the mutants also largely prevented the
alteration of splenic architecture and the development of
splenic sclerosis (Fig. 7 b and not depicted). Strikingly, the
anti-FasL antibody treatment also blocked lymphocyte in-
filtration in the lung (Fig. 7 c). Collectively, these results
show that the entire pathology developing in the animals
lacking Fas on T cells is due to abnormal Fas–FasL interac-
tion, likely reflecting the interaction of the Fas-deficient T
cells with Fas-proficient cells in the environment.
Discussion
A critical role for T and B cells in the development of
ALPS in lpr mice has been deduced from the finding that
both lymphadenopathy and autoimmune disease were sup-
pressed by thymectomy (7, 8) or ablation of B cell develop-
ment (11). Furthermore, several groups have reported that
restoration of Fas expression in T cells of lpr mice can cor-
rect the lymphoproliferative disease (9, 10). Here, we show
that Fas inactivation in T, B, or T plus B cells of C57BL/6
mice is insufficient for the pathogenesis of lymphoprolifera-
tive disease. Similarly, autoantibody formation was dimin-
ished in the T or B cell–specific Fas KOs as compared with
Fas-deficient mice, although the former animals did have
elevated levels of anti-DNA antibodies in the blood as
compared with wild-type controls (unpublished data). The
Figure 7. Prevention of lymphopenia and cell infiltration in the lungs
upon application of anti-FasL antibody. Groups of three mutant and three
control mice were treated with anti-FasL antibody or isotype-matched
hamster IgG1. Two mice from each group were analyzed 8 wk after anti-
body application, and one mouse from each group was analyzed at 12 wk.
(a) FACS® analysis of lymphocytes in inguinal LNs. (b and c) Coimmu-
nostaining of the spleen (b) and lung (c) sections with anti-CD3 (red) and
anti-CD19 (blue) antibody. Shown is the analysis of one set of mice
treated with antibody for 8 wk. (b and c) Bars, 200  m.Fas–Fas Ligand Interaction-mediated Lymphocyte Homeostasis and Pulmonary Fibrosis 1362
attenuated lymphoproliferative disease seen upon lym-
phocyte-specific Fas inactivation on the autoimmune-
prone (C57BL/6 MRL)F1 background further demonstrates
that Fas inactivation in lymphocytes is not sufficient for full
ALPS development, and, in addition, defective Fas expres-
sion in nonlymphoid cell types is required. Along these
lines, it has been reported that the liver may be the initial
site of DN T cell proliferation (34). Such an initial expan-
sion of the FasL-expressing DN T cells may be incompati-
ble with Fas expression on the surrounding cells in this
organ, and it will be interesting to see whether Fas inacti-
vation in both T and liver cells reproduces the develop-
ment of ALPS in lpr mice.
Mice with T cell–specific Fas inactivation developed a
profound lymphopenia over time. In accord with the ear-
lier cell transfer studies (12, 13), this indicates that the
interaction between Fas-deficient, activated T cells and
Fas-expressing, nonlymphoid cells through Fas–FasL inter-
action prevents the development of ALPS as it is seen in
the lpr mouse and human Fas-deficient patients. Absence of
Fas in T cells would have been sufficient for the develop-
ment of lymphoproliferative disease if loss of Fas expression
were not accompanied by a dramatic up-regulation of FasL
in these cells. This is supported by the appearance of DN T
cells in the mutant animals upon application of anti-FasL
antibody, which blocks the interaction between the FasL-
expressing T cells and Fas-expressing non–T cells. In turn,
in lpr mice, the expression of FasL by the DN T cells (32,
33) is compatible with ALPS development, as there are no
Fas-competent cells in the environment with which these
T cells could interact.
In contrast with the rapid development of a fatal wasting
syndrome developing in irradiated MRL mice upon trans-
fer of Fas-deficient congenic BM cells (12, 13), T cell–spe-
cific Fas inactivation in intact mice led to a situation in
which the animals appeared perfectly healthy over the first
months of life. This was true not only for C57BL/6, but
also (MRL C57BL/6)F1 mice (unpublished data). We
think that this dramatic difference in the onset of disease is
due to the different experimental conditions in that in the
cell transfer system, which involves X-irradiation, the Fas-
deficient T cells are confronted with a (Fas proficient) envi-
ronment that may promote a rapid general T cell activa-
tion. Also, it cannot be excluded that other Fas-deficient
hematopoietic cells developing in these animals contribute
to the disease phenotype. In contradistinction, the system
of Cre-mediated Fas inactivation in T cells used in the
present work reconstructs what happens when Fas-defi-
cient T cells lose their Fas–FasL-based homeostatic control
under quasiphysiological conditions. Our results suggest
that the loss of this homeostatic control, accompanied by
FasL up-regulation in concert with chronic T cell activa-
tion, is critical for the gradual loss of lymphocytes in the
mutant animals and their ultimate fatal disease. The acti-
vated cells, arising because of their disturbed homeostatic
control, may directly kill the B cells in the mutant animals
through Fas–FasL interaction. This is in line with the pres-
ence of activated caspase-3 in a substantial fraction of those
cells. The unexpected concomitant loss of naive T cells be-
comes less surprising, considering that experimental evi-
dence that enforced transgenic expression of FasL in a vari-
ety of tissues does not confer immune privilege, but instead
leads to rapid tissue destruction (35–37). Fas expression on
the target cells is dispensable for this to occur, but is re-
quired on the infiltrating cells (36, 38). This implies a cell
death signal that is dependent on Fas–FasL interaction, but
is not mediated by Fas in a cell-autonomous manner.
How can FasL expression on activated, Fas-deficient T
cells mediate the loss of naive T cells? An obvious possibility
is that the FasL-expressing cells destroy the natural habitat of
naive T and probably also B cells by attacking cells in the
environment. Targets for such an attack could be, for exam-
ple, endothelial cells in lymph and blood vessels, known to
be sensitive to Fas-mediated apoptosis in response to inflam-
mation (39). Furthermore, the interaction of the activated T
cells with DCs and macrophages is expected to lead to the
activation of the latter through Fas engagement (40, 41).
This could result in the killing of the Fas-deficient T cells
through cytokines such as TNF to which the mutant cells
may be more sensitive than wild-type cells. Although we
have been unable to obtain experimental support for the lat-
ter mechanism in that we have neither observed a preferen-
tial killing of Fas-deficient T cells in cocultures with acti-
vated DCs, nor an enhanced sensitivity of the mutant T
cells to TNF-  (Nguyen, K., personal communication), our
experiments strongly support the concept that the activated
T cells generate a “hostile” environment in which naive
lymphocytes cannot survive. Thus, the splenic microarchi-
tecture was profoundly disturbed in the mutant animals, and
there was massive cell death in the spleen in situ, as well as
in the areas of the initial T cell infiltration in the lungs.
However, most significantly, B cell loss was observed also in
a situation in which both T and B cells were deficient for
Fas (i.e., the B cells could not be a direct target of the FasL-
expressing activated T cells). The prediction that in this sit-
uation the B cells, similar to the naive T cells would not
contain activated caspase-3, could not be tested because the
double mutant animals were no longer available. The small
fraction of naive T cells that had escaped Cre-mediated Fas
inactivation in the T cell–specific KOs were also lost in the
animals over time (unpublished data), but in this case the
loss could be due to a direct attack by Fas-deficient activated
companion T cells. Other factors may also contribute to the
loss of naive lymphocytes in the mutant animals. Thus, the
observed thymic atrophy, perhaps itself mediated by an at-
tack of activated T cells on the thymic microenvironment,
likely restricts the output of naive T cells over time. Finally,
the Fas signaling pathway has been shown to control not
only T cell death, but also T cell activation and proliferation
(42–46). This may also contribute to the loss of naive T cells
in the mutant animals.
The fatal pulmonary disease developing in the mutant
animals seems to be initiated by lymphocytes infiltrating
the lungs and could thus also be due to an attack of acti-Hao et al. 1363
vated, Fas-deficient T cells against Fas-expressing cells in
their environment. It is not surprising that the lung is pref-
erentially targeted by such an attack, given that it is con-
stantly exposed to antigenic stimuli such that activated T
cells could easily be recruited into the resulting immune re-
actions. That the infiltrating T cells in the lungs of the mu-
tant animals indeed kill cells in their environment, likely
including alveolar epithelial or endothelial cells, is sug-
gested by the colocalization of TUNEL positive cells and T
cell infiltrates in the histological sections (Fig. 6 b). In the
present scenario, this is expected to lead to a vicious cycle
of inflammatory processes for a variety of reasons. Thus, it
is known that FasL expression in various tissues, aside from
targeting them for rapid destruction, induces neutrophil in-
filtration and local inflammation (35–37). The former
could result from the observed MIP-2 production (Fig. 5 c)
by activated macrophages recruited into the lesions, injured
lung epithelial cells, and also extravasated neutrophils (28).
Activated macrophages upon engagement of apoptotic lung
epithelial cells (47) and the apoptotic cells themselves (48)
produce TGF- 1 (Fig. 5 c, elevated in the BALF) that sup-
presses the inflammation (49, 50), inhibits FasL expression
(51) and neutrophil activation (52), and causes pulmonary
fibrosis (29–31). In turn, massive TGF- 1 production en-
hances Fas-mediated apoptosis of lung epithelial cells (53)
and, thus, increases the inflammatory reaction additionally.
Phenotypically, the lung disease developing in the ani-
mals resembles human IPF, a fatal chronic diffuse interstitial
pneumonia of unknown cause and characterized histo-
pathologically by inflammation and fibrosis of the lung pa-
renchyma (17). Despite extensive efforts, no animal model
of persistent and progressive pulmonary fibrosis was so far
available (17). Human IPF and the disease developing in
our animals resemble each other in onset at advanced age,
chronic progression, massive infiltration of similar types of
inflammatory cells, increased production of IL-8/MIP-2
and TGF- 1, and the development of pulmonary fibrosis.
The wasting syndrome seen in the mouse model but not
the human disease is possibly due to massive tissue destruc-
tion by FasL-expressing T cells in the former. Although it
is interesting to note that in mice, Fas–FasL interaction
plays a critical role in the development of acute bleomycin-
induced pulmonary fibrosis (54) and silica-induced pulmo-
nary silicosis (55), its possible role in IPF remains specula-
tive at this point. In its limits, the present experimental
system may address this issue and provide a mouse model of
IPF in the human, highlighting in parallel the potentially
dramatic impact of somatic mutation on cellular homeosta-
sis through dysregulated gene expression.
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